-

GA4GH/DREAM Workflow Execution Challenge
GA4GH/DREAM Workflow Execution Challenge
Launches July 5 (Pre-registration is open)
The goal of this challenge is to evaluate systems and platforms for executing portable analysis workflows in the interest of developing common standards and best practices. Participants will run high quality genomics workflows in their system of choice to assess portability and reproducibility in a concrete way.
-

Parkinson’s Disease Digital Biomarker DREAM Challenge
Parkinson’s Disease Digital Biomarker DREAM Challenge
Launching July 6, 2017 (Pre-registration is open)
Using data collected through two Parkinson’s Disease mobile research studies, the goal of this challenge is to identify the best methods for processing mobile sensor data in order to distinguish gait and motor differences between Parkinson’s Disease patients and controls.
-

NCI-CPTAC DREAM Proteogenomics Challenge
NCI-CPTAC DREAM Proteogenomics Challenge
Launches June 26 (Registration is open)
This challenge will use public and novel proteogenomic data generated by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) to benchmark an understanding of the interfaces between different layers of information in a population of cancer cells.
-

Multiple Myeloma DREAM Challenge
Multiple Myeloma DREAM Challenge
June 30 (Pre-registration is open)
The Multiple Myeloma DREAM Challenge provides an opportunity to combine integration of large scale molecular and clinical data and state of the art analytical approaches to facilitate risk stratification in over 25,000 patients in the US alone. Additionally, it provides the ability to benchmark novel methods with the greatest potential to yield patient care benefits in the future.
-

The Digital Mammography DREAM Challenge.
The Digital Mammography DREAM Challenge.
June 29, 2016- May 2017 (competitive phase closed)
With generous support from the Laura and John Arnold Foundation this $1.2 million Challenge, one of two large prize Coding4Cancer Challenges, seeks to improve the accuracy of breast cancer detection and reduce the current rate of patient callbacks.



Keller A, Gerkin R, et. al.